Reprieve Cardiovascular Secures $61M to Advance Pivotal FASTR II Heart Failure Trial

Milford, Mass.–based Reprieve Cardiovascular has closed an oversubscribed $61 million Series B financing round to accelerate its pivotal FASTR II clinical trial and prepare for commercialization of the Reprieve® System. The round was led by Deerfield Management, with participation from Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, Cadence Capital, and a strategic investor. Funding includes both equity and debt components.

The first patient in FASTR II was enrolled by Washington University School of Medicine in St. Louis. The global randomized pivotal study will assess whether the Reprieve System can deliver faster, more effective decongestion than optimal diuretic therapy in patients hospitalized with acute decompensated heart failure (ADHF). Up to 400 patients will be enrolled across sites in the U.S. and Europe, with results intended to support a future premarket approval submission in the United States.

The Reprieve System is designed to personalize decongestion by combining real-time physiological monitoring with automated diuretic dosing recommendations, while replenishing saline to protect kidney function. The goal is to optimize fluid removal, improve outcomes, and reduce hospital readmissions, addressing limitations of conventional diuretic therapy.

FASTR II builds on the company’s earlier FASTR pilot study, which met both primary efficacy and safety endpoints. CEO Mark Pacyna noted that the new funding positions the company to generate the clinical and economic evidence necessary for regulatory clearance and market adoption. Deerfield’s David Neustaedter and Rex Health Ventures’ Anita Watkins both emphasized the system’s potential to address a significant unmet need in heart failure management.